Německý index DAX ve čtvrtek mírně oslabil. Největší růst zaznamenala německá polovodičová společnosti Infineon Technologies (+6,9 %) poté, co analytici z MP Capital Markets zvýšili doporučení ze stupně „hold“ na „buy“. Analytici však zároveň zachovali cílovou cenu pro akcie na 84 EUR. Dále se dařilo též společnostem HOCHTIEF (+2,5 %) a RWE (+2,0 %). Naopak odepisovaly společnosti Qiagen (-2,9 %), Munich Re (-2,8 %) a Hannover Re (-2,7 %).
Naopak nepatrně posílil celoevropský index STOXX Europe 600. Nejvíce přispěly k růstu sektory informačních technologií (+1,88 %), energií (+1,18 %) a průmyslu (+0,24 %). Naopak ztrácely sektory zdravotní péče (-1,05 %), nemovitostí (-0,89 %) a komunikačních služeb (-0,62 %).
Index DAX -0,15 % na 26006,53 b. Nejsilnější akcie Změna Nejslabší akcie Změna Infineon Technologies (IFX) +6,9 % Qiagen (QIA) -2,9 % HOCHTIEF AG (HOT) +2,5 % Munich Re (MUV2) -2,8 % RWE (RWE) +2,0 % Hannover Rueck SE (HNR1) -2,7 % Commerzbank AG (CBK) +1,6 % Vonovia (VNA) -2,2 % Siemens Energy (ENR) +1,3 % SAP (SAP) -1,6 % Zdroj: Bloomberg
AXQ Capital LP lifted its holdings in Qiagen N.V. (NYSE: QGEN) by 58.9% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,910 shares of the company's stock after purchasing an additional 13,683 shares during the quarter. AXQ Capital LP's
A SPECIAL WELCOME GIFT FROM ZACKS.COM Zacks' 7 Strongest Buys for September, 2026 See our "best of the best" short-term stocks. Hand-picked from 220 new Strong Buys, they could be the most profitable stocks you own over the next 90 days. Recent picks have climbed as much as +97.3% within 30 days. Our new recommendations may soar just as high.
A SPECIAL WELCOME GIFT FROM ZACKS.COM Zacks' 7 Strongest Buys for September, 2026 See our "best of the best" short-term stocks. Hand-picked from 220 new Strong Buys, they could be the most profitable stocks you own over the next 90 days. Recent picks have climbed as much as +97.3% within 30 days. Our new recommendations may soar just as high. Today's market dip makes now an ideal time to get in.
loading...
Primed to grow right now with long-term potential gains of 2X and more.
Primed to grow right now with long-term potential gains of 2X and more.
The pharmaceutical industry continues to grow thanks to an aging population and rising demand for new treatments. Which pharma stocks are best?
The pharmaceutical industry continues to grow thanks to an aging population and rising demand for new treatments. Which pharma stocks are best?
The airline industry covers a wide range of business models and opportunities. See our picks for the Best Airline Stocks to buy now.
The airline industry covers a wide range of business models and opportunities. See our picks for the Best Airline Stocks to buy now.
Here are our picks for the best publicly traded companies in the cryptocurrency business.
Here are our picks for the best publicly traded companies in the cryptocurrency business.
This oil and natural gas company has seen the Zacks Consensus Estimate for its current year earnings increase 241.2% over the last 60 days.
This oil and natural gas company has seen the Zacks Consensus Estimate for its current year earnings increase 241.2% over the last 60 days.
SPCX briefly reclaimed a $2 trillion market cap as Starlink growth, launch dominance and AI ambitions fueled investor optimism despite execution risks.
SPCX briefly reclaimed a $2 trillion market cap as Starlink growth, launch dominance and AI ambitions fueled investor optimism despite execution risks.
The consensus for today is expected to show August jobs up 55,000 (up 53K in the private sector and 2K in the public sector), while the unemployment rate is forecast at 4.2%.
The consensus for today is expected to show August jobs up 55,000 (up 53K in the private sector and 2K in the public sector), while the unemployment rate is forecast at 4.2%.
Amazon, AbbVie and Alibaba face contrasting growth drivers and challenges, from AI investment and drug launches to costly spending cycles.
Amazon, AbbVie and Alibaba face contrasting growth drivers and challenges, from AI investment and drug launches to costly spending cycles.
›
‹
Featured Zacks Rank Stocks Learn to Profit from the Zacks Rank
#1 Rank After transitioning from a crypto miner to an AI company, things are looking good.
#5 Rank Tobacco stocks have had a bit of a resurgence with the introduction of new products but analysts are starting to pump the b
Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers Zacks #1 Rank Top Movers for Value Growth Momentum VGM Income Company Symbol Price %Chg Motorsport... MSGM 4.45 +10.70% EuroDry EDRY 55.14 +5.94% Abercrombie... ANF 149.62 +4.24% Polaris PII 63.46 +3.88% TAL Educati... TAL 12.36 +3.09% Zacks #1 Rank Top Movers7/16 The Zacks #1 Rank List is the best place to start your stock search each morning. It's made up of the top 5% of stocks with the most potential. Each weekday, you can quickly see the Zacks #1 Rank Top Movers from Value to Growth, Momentum and Income, even VGM Score.
Go to Zacks Rank #1 Top Movers
Full Zacks #1 Rank List8/16 You can see the full Zacks #1 Rank List or narrow it down to Zacks #1 Rank Stocks with a Value, Growth, Momentum or Income Style Score of A or B. Plus, you can see the Zacks #1 Rank Stocks with a VGM of A or B. You can also sort the list with criteria you choose, view Additions and Deletions by day, and Performance.
Symbol Time Expected Reported %Surprise CURV 16:06 -0.03 -0.04 -33.33 VBNK 07:04 0.34 0.27 -20.59 LE 06:46 0.10 0.09 -10.00 CPB 07:15 0.40 0.39 -2.50 EPS Negative Surprises for Sep 04, 2026
Upcoming Earnings ESP View More Symbol ESP Most Accurate Estimate Consensus Estimate AVO 21.74% 0.14 0.12 LMNR 5.26% 0.20 0.19 INNV 5.88% 0.09 0.09 Featured Stock Picks
Best Airline Stocks to Buy Now September 2026 The airline industry covers a wide range of business models and opportunities. See our picks for the Best Airline Stocks to buy now.
Best Crypto Stocks to Buy for September 2026 Here are our picks for the best publicly traded companies in the cryptocurrency business.
Best Pharmaceutical Stocks to Buy for September 2026 The pharmaceutical industry continues to grow thanks to an aging population and rising demand for new treatments. Which pharma stocks are best?
Best Biotech Stocks to Buy for September 2026 Biotech stocks are one of the most dynamic sectors in the market, combining scientific innovation with substantial financial opportunity. Here are some top current buys.
Best Gold Stocks to Buy for September 2026 Gold stocks, or shares of companies involved in mining or streaming the precious metal, offer investors a way to participate indirectly in gold price booms.
Německý index DAX ve čtvrtek posílil. Nejvíce se dařilo akciím Volkswagenu (+3,6 %), když ve středu oznámil změnu vedení v jeho americké divizi. Cílem managementu je oživit svůj byznys ve Spojených státech.
Dařilo se dnes také akciím společnosti Vonovia (+2,6 %) a HOCHTIEF (+2,5 %). Naopak pokles zaznamenaly akcie Rheinmetallu (-1,9 %), Qiagenu (-1,8 %) a Siemens Healthineers (-1,7 %).
Rovněž posílil evropský index STOXX600. Nejvíce přispěly k růstu sektory financí (+1,35 %), komunikačních služeb (+1,19 %) a nemovitostí (+1,11 %). Naopak ztrácely sektory nezbytné spotřeby (-0,63 %), energií (-0,35 %) a IT (-0,33 %).
Index DAX +0,64 % na 26004,16 b. Nejsilnější akcie Změna Nejslabší akcie Změna Volkswagen (VOW3) +3,6 % Rheinmetall AG (RHM) -1,9 % Vonovia (VNA) +2,6 % Qiagen (QIA) -1,8 % HOCHTIEF AG (HOT) +2,5 % Siemens Healthineers (SHL) -1,7 % SAP (SAP) +2,3 % Merck (MRK) -1,5 % Siemens Energy (ENR) +2,2 % Fresenius Medical Care (FME) -1,4 % Zdroj: Bloomberg, WSJ
VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. Building on the trusted QIAsymphony platform, with more than 3,300 cumulative placements worldwide, QIAsymphony Connect helps clinical laboratories standardize extraction across diverse assay workflows. The platform delivers highly concentrated DNA and.
BioLife Solutions (NASDAQ:BLFS – Get Free Report) and Qiagen (NYSE:QGEN – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability.
Institutional and Insider Ownership 93.2% of BioLife Solutions shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 2.2% of BioLife Solutions shares are owned by insiders. Comparatively, 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability This table compares BioLife Solutions and Qiagen’s net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets BioLife Solutions 53.29% 2.70% 2.49% Qiagen 19.49% 14.47% 8.34% Analyst Ratings This is a summary of current ratings for BioLife Solutions and Qiagen, as reported by MarketBeat.com. Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLife Solutions 1 8 1 1 2.18 Qiagen 0 9 4 1 2.43 BioLife Solutions currently has a consensus price target of $31.38, indicating a potential downside of 13.76%. Qiagen has a consensus price target of $43.93, indicating a potential upside of 1.96%. Given Qiagen’s stronger consensus rating and higher probable upside, analysts clearly believe Qiagen is more favorable than BioLife Solutions.
Earnings and Valuation This table compares BioLife Solutions and Qiagen”s gross revenue, earnings per share (EPS) and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioLife Solutions $96.21 million 18.48 -$4.59 million $1.16 31.36 Qiagen $2.09 billion 4.25 $424.88 million $1.95 22.09 Qiagen has higher revenue and earnings than BioLife Solutions. Qiagen is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk BioLife Solutions has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500.
Summary Qiagen beats BioLife Solutions on 9 of the 14 factors compared between the two stocks.
(Get Free Report)
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
About Qiagen (Get Free Report)
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare. Jon Pratt most recently served as President and CEO of Filtration Group, leading the business through the completion of its sale to Parker-Hannifin Corpor.
Frankfurtská burza dnes uzavřela obchodování v záporu, když index DAX oslabil o 0,42 %. Největší růst zaznamenaly akcie Qiagen (+3,1 %), dále Symrise (+1,9 %) a HeidelbergCement (+1,5 %). Naopak nejvíce oslabily akcie Adidas (-3,1 %), MTU Aero Engines (-1,8 %) a Deutsche Telekom (-1,6 %).
Evropský index STOXX 600 se nyní pohybuje v záporném teritoriu a oslabuje o 0,12 %. V rámci sektorů se nejvíce daří energetice (+1,23 %), utilitám (+0,48 %) a materiálům (+0,40 %). Naopak největší ztráty zaznamenává zbytná spotřeba (-1,29 %), komunikační služby (-0,76 %) a průmysl (-0,38 %).
Index DAX -0,42 % na 25983,04 b. Nejsilnější akcie Změna Nejslabší akcie Změna Qiagen (QIA) +3,1 % Adidas (ADS) -3,1 % Symrise (SY1) +1,9 % MTU Aero Engines (MTX) -1,8 % HeidelbergCement (HEI) +1,5 % Deutsche Telekom (DTE) -1,6 % Continental (CON) +1,1 % Airbus (AIR) -1,5 % E.ON (EOAN) +1,0 % Scout24 SE (G24) -1,5 %
Zdroj: Bloomberg
Německé akcie, měřené indexem DAX, ve středu oslabily o 0,14 % na 26 091,33 b.
Dařilo se akciím koncernu Volkswagen (+2,5 %), biotechnologické společnosti QIAGEN (+2,1 %) a softwarové společnosti SAP (+1,9 %). Naopak oslabovaly akcie polovodičové společnosti Infineon Technologies (-4,0 %), zbrojaře Rheinmetall (-2,9 %) a zajišťovny Hannover Re (-2,2 %).
Evropské akcie, měřené indexem STOXX Europe 600, jsou téměř beze změny, sektorově jde ale o rozpadlou emulzi, přičemž se daří základním materiálům (+1,92 %), zdravotní péči (+1,17 %) a zbytné spotřebě (+0,87 %). Naopak oslabují sektory IT (-1,27 %), financí (-1,18 %) a utilit (-1,02 %).
Index DAX -0,14 % na 26 091,33 b. Nejsilnější akcie Změna Nejslabší akcie Změna Volkswagen (VOW3) +2,5 % Infineon Technologies (IFX) -4,0 % Qiagen (QIA) +2,1 % Rheinmetall AG (RHM) -2,9 % SAP (SAP) +1,9 % Hannover Rueck SE (HNR1) -2,2 % Symrise (SY1) +1,6 % MTU Aero Engines (MTX) -2,1 % BASF (BAS) +1,6 % HOCHTIEF AG (HOT) -1,9 % Zdroj: Bloomberg
Frankfurtská burza zakončuje úterní seanci růstem. Nejvíce posílily akcie Siemens Energy (+2,6 %), RWE (+1,8 %) a Deutsche Telekom (+1,6 %). Naopak v červených číslech zakončily akcie Qiagen (-3,6 %), Adidas (-3,1 %) a Zalando (-3,0 %). Evropský index STOXX600 zakončil úterý na zelené nule. Dařilo se především segmentům IT (+1,7 %), energií (+1,6 %) a komunikačním službám (+0,9 %). Na opačném spektru zakončily den segmenty nezbytné spotřeby (-1,0 %), zdravotní péče (-0,5 %) a financí (-0,4 %).
Index DAX +0,3 % na 26 323,88 b. Nejsilnější akcie Změna Nejslabší akcie Změna Siemens Energy (ENR) +2,6 % Qiagen (QIA) -3,6 % RWE (RWE) +1,8 % Adidas (ADS) -3,1 % Deutsche Telekom (DTE) +1,6 % Zalando (ZAL) -3,0 % Scout24 (G24) +1,5 % Merck (MRK) -2,4 % BMW (BMW) +1,4 % Daimler Truck Holding AG (DTG) -2,0 % Zdroj: Bloomberg
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx BCID GPF Plus AMR Panel, the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance.
The clearance expands QIAGEN’s U.S. syndromic testing portfolio into bloodstream infection diagnostics, the fourth major infectious disease area covered by the QIAstat-Dx platform, which is available in more than 100 countries and with more than 5,200 cumulative placements as of the end of 2025.
The QIAstat-Dx BCID GPF Plus AMR Panel detects 20 gram-positive bacterial and fungal pathogen targets as well as a broad pan gram-negative target together with 10 genetic antimicrobial resistance markers from positive blood culture samples in about one hour. The rapid identification of pathogens and resistance gene markers can support informed treatment decisions, antimicrobial stewardship and infection prevention measures.
Bloodstream infections are associated with significant morbidity and mortality and can rapidly progress to sepsis, a life-threatening reaction to an infection that causes your immune system to harm healthy tissues and organs. An estimated 1.7 million adults in the U.S. develop sepsis each year1, highlighting the importance of providing clinicians with timely diagnostic information.
“Every hour, even minutes, count with bloodstream infections,” said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. “This clearance gives U.S. laboratories a fast and integrated way to identify pathogens and key genetic antimicrobial resistance markers, supporting more informed treatment decisions and responsible antibiotic use. It also establishes the first member of a broader QIAstat-Dx bloodstream infection panel family planned for the U.S.”
The QIAstat-Dx system integrates sample preparation, multiplex PCR testing and data analysis into a single workflow. It is designed to provide rapid and easy-to-interpret results while reducing hands-on time for laboratory professionals.
The FDA clearance also lays the foundation for the continued expansion of QIAGEN’s bloodstream infection testing portfolio in the U.S. A complementary QIAstat-Dx BCID GN Plus AMR Panel, designed to detect gram-negative pathogens and associated genetic antimicrobial resistance markers, is currently under FDA review.
QIAGEN has been consistently expanding the QIAstat-Dx menu for the U.S., broadening the platform across four major infectious disease areas: respiratory, gastrointestinal, central nervous system and now bloodstream infections. The portfolio includes the QIAstat-Dx Respiratory Panel Plus, the QIAstat-Dx Respiratory Panel Mini, the QIAstat-Dx Gastrointestinal Panel 2, the QIAstat-Dx GI Panel 2 Mini B, the QIAstat-Dx GI Panel 2 Mini B&V, the QIAstat-Dx Meningitis/Encephalitis Panel and the newly FDA-cleared QIAstat-Dx BCID GPF Plus AMR Panel. This reflects QIAGEN's strategy of building a comprehensive infectious disease testing menu on a single integrated platform.
For more information about the QIAstat-Dx BCID GPF Plus AMR Panel and the QIAstat-Dx system, visit www.qiagen.com/applications/syndromic-testing.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and Molecular Diagnostics (clinical healthcare). As of June 30, 2026, QIAGEN employed about 5,500 people across more than 35 locations. For more information, visit www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. These include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to QIAGEN's filings with the U.S. Securities and Exchange Commission.
1 Centers for Disease Control and Prevention (CDC). About Sepsis. Available at: https://www.cdc.gov/sepsis/about/index.html (accessed August 2026).
Have you assessed how the international operations of Qiagen (QGEN - Free Report) performed in the quarter ended June 2026? For this diagnostic products maker, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects.
The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and growth path. It has become essential for investors to comprehend how much a company relies on these foreign markets, as this understanding reveals the firm's potential for consistent earnings, its capacity to harness different economic cycles, and its overall growth prospects.
Presence in international markets can act as a hedge against domestic economic downturns and provide access to faster-growing economies. However, this diversification also brings complexities due to currency fluctuations, geopolitical risks and differing market dynamics.
While analyzing QGEN's performance for the last quarter, we found some intriguing trends in revenues from its overseas segments that Wall Street analysts commonly model and monitor.
The company's total revenue for the quarter amounted to $535.04 million, showing rise of 0.3%. We will now explore the breakdown of QGEN's overseas revenue to assess the impact of its international operations.
Exploring QGEN's International Revenue PatternsDuring the quarter, Asia Pacific, Japan and Rest of World contributed $72 million in revenue, making up 13.5% of the total revenue. When compared to the consensus estimate of $73.53 million, this meant a surprise of -2.08%. Looking back, Asia Pacific, Japan and Rest of World contributed $70 million, or 14.2%, in the previous quarter, and $73 million, or 13.7%, in the same quarter of the previous year.
Europe, Middle East and Africa generated $178 million in revenues for the company in the last quarter, constituting 33.3% of the total. This represented a surprise of -2.24% compared to the $182.07 million projected by Wall Street analysts. Comparatively, in the previous quarter, Europe, Middle East and Africa accounted for $173 million (35.1%), and in the year-ago quarter, it contributed $179 million (33.6%) to the total revenue.
Projected Revenues in Foreign MarketsThe current fiscal quarter's total revenue for Qiagen, as projected by Wall Street analysts, is expected to reach $541.05 million, reflecting an increase of 1.6% from the same quarter last year. The breakdown of this revenue by foreign region is as follows: Asia Pacific, Japan and Rest of World is anticipated to contribute 14.4% or $77.75 million, and Europe, Middle East and Africa 35.7% or $193.33 million.
For the full year, a total revenue of $2.14 billion is expected for the company, reflecting an increase of 2.4% from the year before. The revenues from Asia Pacific, Japan and Rest of World and Europe, Middle East and Africa are expected to make up 14.1%, and 35.1% of this total, corresponding to $301.87 million, and $750.87 million, respectively.
In ConclusionRelying on global markets for revenues presents both prospects and challenges for Qiagen. Therefore, scrutinizing its international revenue trends is key to effectively forecasting the company's future outlook.
In an era of growing international interdependencies and escalating geopolitical disputes, Wall Street analysts are vigilant in tracking these trends for businesses with a global reach, in order to refine their predictions of earnings. It should be noted, however, that a multitude of other elements, such as a company's domestic position, also play a significant role in shaping the earnings forecasts.
At Zacks, we place significant importance on a company's evolving earnings outlook. This is based on empirical evidence demonstrating its strong influence on a stock's short-term price movements. Invariably, there exists a positive relationship -- an upward revision in earnings estimates is typically mirrored by a rise in the stock price.
The Zacks Rank, our proprietary stock rating mechanism, demonstrates a notable performance history confirmed through external audits. It effectively utilizes the power of earnings estimate revisions to act as a predictor of a stock's price performance in the near term.
At present, Qiagen holds a Zacks Rank #3 (Hold). This ranking implies that its near-term performance might mirror the overall market movement. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Reviewing Qiagen's Recent Stock Price TrendsOver the past month, the stock has gained 1.9% versus the Zacks S&P 500 composite's 3.4% increase. The Zacks Medical sector, of which Qiagen is a part, has declined 0.4% over the same period. The company's shares have increased 28.3% over the past three months compared to the S&P 500's 6% increase. Over the same period, the sector has risen 10.8%
Německé akcie měřené indexem DAX otevírají týden pozitivně.
GEA Group ve 2Q překonala očekávání trhu na hlavních ukazatelích. Očištěný zisk EBITDA dosáhl 251 mil. EUR oproti konsenzu 246,3 mil. EUR a EBITDA marže činila 17,4 % proti očekávaným 17,2 %. Tržby dosáhly 1,44 mld. EUR a objednávky 1,50 mld. EUR, v obou případech nad konsenzem trhu. Společnost zároveň ponechala celoroční výhled beze změny. Nadále očekává organický růst tržeb o 6 až 8 % a očištěnou EBITDA marži mezi 17,0 až 17,4 %. Akcie GEA Group +0,8 %.
Společnosti Qiagen byla analytikem Barclays zvýšena cílová cena z 38 USD na 40 USD. Doporučení bylo ponecháno na stupni „Equal-Weight“. Akcie Quaigen +2,5 %.
Index DAX +0,06 % na 26334,66 b. Nejsilnější akcie Změna Nejslabší akcie Změna Qiagen (QIA) +2,5 % Scout24 SE (G24) -1,3 % Infineon Technologies (IFX) +2,2 % Munich Re (MUV2) -1,1 % Siemens Energy (ENR) +1,7 % Beiersdorf AG (BEI) -1,0 % Allianz (ALV) +1,5 % Mercedes-Benz Group AG (MBG) -0,9 % Merck (MRK) +1,1 % Volkswagen (VOW3) -0,9 %
Zdroj: Bloomberg
Marek Krejčiřík
Fio banka, a.s.
Prohlášení
Související odkazy Německé akcie ve čtvrtek posílily Frankfurtská burza v úvodu mírně posiluje, společnost Deutsche Boerse reportovala za 1Q Frankfurtská burza v úvodu obchodování ztrácí Frankfurtská burza zakončila úterní seanci v záporu
Strategic Buy Lights Up This Biotech Stock: Time to Invest?Qiagen NYSE: QGEN reported second-quarter 2026 results above its prior outlook, with net sales of $535 million, unchanged year over year on both a reported and constant-exchange-rate basis. The company had forecast an approximately 2% decline at constant exchange rates. Adjusted diluted earnings per share were $0.62, exceeding guidance of at least $0.60 at constant exchange rates.
Chief Executive Officer Thierry Bernard said the company’s growth pillars rose 5% at constant exchange rates during the quarter, led by Sample Technologies, QIAcuity digital PCR and QIAGEN Digital Insights. He said QuantiFERON latent tuberculosis testing returned to growth despite a significant decline in U.S. immigration testing demand, while QIAstat-Dx faced a difficult comparison in respiratory testing.
Get Qiagen alerts:
Product-group performance varied Sample Technologies sales increased 9% at constant exchange rates, supported by automated consumables and higher instrument sales compared with the prior-year period. Diagnostic Solutions revenue declined 2% at constant exchange rates. Within that segment, QuantiFERON grew 1%, as demand across most testing groups outweighed lower immigration testing demand in the U.S. and Middle East.
QIAstat-Dx sales fell 7% at constant exchange rates. Growth in gastrointestinal and meningitis panels was offset by lower respiratory-panel sales against a strong prior-year comparison. PCR and nucleic acid amplification sales declined 8%, although QIAcuity delivered double-digit growth driven by consumables demand. The growth in QIAcuity was more than offset by weaker OEM demand, according to Chief Financial Officer Roland Sackers.
Genomics and next-generation sequencing sales rose 2% at constant exchange rates. QIAGEN Digital Insights posted solid single-digit growth, while consumables for universal NGS panels used on third-party sequencers grew more than 20%. Lower sales of other genomics products moderated the segment’s overall growth rate.
Americas sales rose 1% at constant exchange rates, including 2% growth in North America. EMEA sales declined 2%, with gains in Spain, Belgium and Poland offset by declines in Germany, France and Italy. Asia-Pacific sales declined 2%, though the region excluding China grew at a low-single-digit rate and Japan posted high-teens growth. China sales declined in the low teens year over year, but improved sequentially at a double-digit percentage rate. Margins and cash flow remained high Adjusted operating income declined 2% to $157 million, while the adjusted operating margin was 29.4%, compared with 29.9% in the second quarter of 2025. Sackers said disciplined cost management and efficiency measures helped offset product-mix-related pressure on gross margin. The adjusted cost margin was 66.2%, down from 66.7% a year earlier.
The operating margin improved by 200 basis points sequentially from 27.4% in the first quarter. Qiagen’s adjusted tax rate was 18%, within its 17% to 18% target range.
Operating cash flow totaled $301 million for the first six months of 2026, unchanged from the same period in 2025. The figure included approximately $20 million in cash payments tied to efficiency and restructuring programs, as well as a planned inventory increase ahead of product launches. Days sales outstanding improved to approximately 55 days from 57 days at the end of 2025, while days inventory outstanding increased to 153 from 149.
The company completed a $500 million synthetic share repurchase in January and paid an approximately $72 million annual dividend in July. The dividend rose 40% to $0.35 per share from $0.25 in 2025.
New launches underpin second-half expectations Bernard highlighted progress in the company’s automation portfolio, including the commercial launch of QIAsymphony Connect and early placements of QIAsprint Connect. QIAmini remains scheduled for a fall launch, with beta field testing in North America expected to begin in coming weeks.
In diagnostics, Qiagen launched two QIAstat-Dx bloodstream infection panels in Europe that collectively detect 33 pathogens and 28 antimicrobial resistance markers in about one hour. Bernard said the company expects FDA approval for the panels by year-end. Qiagen also expects its complicated urinary tract infection panel to be available in Europe during the second half of 2027.
The company plans to launch new QIAcuity gene-expression assays and a multiplex kit for up to 12 RNA targets in a single reaction during the second half of 2026. It is also working with DiaSorin and Inpeco on a fully automated QuantiFERON Sample to Insight workflow, targeted for launch in the second half of 2027.
Guidance reaffirmed; strategic review continues Qiagen reaffirmed its full-year outlook for constant-exchange-rate sales growth of about 1% to 2% and adjusted diluted EPS of at least $2.43. For the third quarter, the company forecast sales growth of approximately 1% to 2% at constant exchange rates and adjusted diluted EPS of at least $0.62.
Sackers said the company expects sales growth to improve from a 1% decline in the first half to roughly 3% to 4% in the second half. Management cited the end of headwinds from discontinued NeuMoDx and bioinformatics portfolios, contributions from recent product launches, Parse single-cell analysis performance ahead of its approximately $40 million 2026 sales target, and modestly improving U.S. life-science funding conditions.
Bernard said Qiagen’s CEO search and strategic review are complementary but independent processes. He reiterated that the CEO transition is expected during the second half of 2026 and said the company will continue evaluating options intended to increase shareholder and stakeholder value.
About Qiagen (NYSE:QGEN)Qiagen NV NYSE: QGEN is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company's solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.
The company's product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Should You Invest $1,000 in Qiagen Right Now?Before you consider Qiagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Qiagen wasn't on the list.
While Qiagen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for Q2 2026, with net sales and adjusted diluted earnings per share exceeding the outlook while maintaining a high level of profitability. Net sales for Q2 2026 were unchanged at $535 million on a reported basis and at constant exchange rates (CER) compared to Q2 2025, exceeding the outlook for an approximately 2% CER decline. QIAGEN's growth pillars together delivered 5% CER gro.
Qiagen (QGEN - Free Report) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.6 per share. This compares to earnings of $0.63 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +3.33%. A quarter ago, it was expected that this diagnostic products maker would post earnings of $0.55 per share when it actually produced earnings of $0.54, delivering a surprise of -1.82%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Qiagen, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $535.04 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 1.35%. This compares to year-ago revenues of $533.54 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Qiagen shares have lost about 10.6% since the beginning of the year versus the S&P 500's gain of 13%.
What's Next for Qiagen?While Qiagen has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Qiagen was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.64 on $552.19 million in revenues for the coming quarter and $2.43 on $2.14 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 44% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Opus Genetics, Inc. (IRD - Free Report) , has yet to report results for the quarter ended June 2026.
This company is expected to post quarterly loss of $0.15 per share in its upcoming report, which represents a year-over-year change of -25%. The consensus EPS estimate for the quarter has been revised 1.5% lower over the last 30 days to the current level.
Opus Genetics, Inc.'s revenues are expected to be $3.02 million, up 5% from the year-ago quarter.
For the quarter ended June 2026, Qiagen (QGEN - Free Report) reported revenue of $535.04 million, up 0.3% over the same period last year. EPS came in at $0.62, compared to $0.63 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $527.94 million, representing a surprise of +1.35%. The company delivered an EPS surprise of +3.33%, with the consensus EPS estimate being $0.60.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Qiagen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Sales by Product Groups- Diagnostic solutions- QIAstat-Dx: $32 million versus the four-analyst average estimate of $36.58 million. The reported number represents a year-over-year change of -5.9%.Sales by Product Groups- Diagnostic solutions- QuantiFERON: $131 million versus $127.81 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +1.6% change.Sales by Product Groups- Diagnostic solutions- Other: $40 million versus the three-analyst average estimate of $29.5 million. The reported number represents a year-over-year change of 0%.Sales by Product Groups- Other: $15 million versus $14.17 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -31.8% change.Sales by Product Groups- PCR / Nucleic acid amplification: $74 million versus $69.7 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -7.5% change.Sales by Product Groups- Genomics / NGS: $61 million versus $59.47 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +3.4% change.Sales by Product Groups- Diagnostic solutions: $204 million versus the three-analyst average estimate of $202.46 million. The reported number represents a year-over-year change of -1%.Sales by Product Groups- Sample technologies: $182 million compared to the $181.19 million average estimate based on three analysts. The reported number represents a change of +9.6% year over year.View all Key Company Metrics for Qiagen here>>>
Shares of Qiagen have returned +9.3% over the past month versus the Zacks S&P 500 composite's +3.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
The market expects Qiagen (QGEN - Free Report) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
The earnings report, which is expected to be released on August 5, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus EstimateThis diagnostic products maker is expected to post quarterly earnings of $0.60 per share in its upcoming report, which represents a year-over-year change of -4.8%.
Revenues are expected to be $527.94 million, down 1.1% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.78% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Qiagen?For Qiagen, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -0.28%.
On the other hand, the stock currently carries a Zacks Rank of #4.
So, this combination makes it difficult to conclusively predict that Qiagen will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Qiagen would post earnings of $0.55 per share when it actually produced earnings of $0.54, delivering a surprise of -1.82%.
Over the last four quarters, the company has beaten consensus EPS estimates two times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Qiagen doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
An Industry Player's Expected ResultsAmong the stocks in the Zacks Medical - Biomedical and Genetics industry, Rhythm Pharmaceuticals, Inc. (RYTM - Free Report) , is soon expected to post loss of $0.82 per share for the quarter ended June 2026. This estimate indicates a year-over-year change of -9.3%. This quarter's revenue is expected to be $65.87 million, up 35.8% from the year-ago quarter.
The consensus EPS estimate for Rhythm Pharmaceuticals has remained unchanged over the last 30 days. However, a higher Most Accurate Estimate has resulted in an Earnings ESP of +1.46%.
When combined with a Zacks Rank of #3 (Hold), this Earnings ESP indicates that Rhythm Pharmaceuticals will most likely beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates two times.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Německé akcie měřené indexem DAX uzavřely obchodní týden pozitivně.
Největší růst zaznamenaly akcie SAP (+9,3 %), dále Siemens Healthineers (+3,0 %) a Fresenius (+2,2 %). Naopak nejvíce oslabily akcie Volkswagen (-2,0 %), Infineon Technologies (-1,7 %) a Adidas (-1,6 %).
Evropský index STOXX 600 se pohybuje v kladném teritoriu a posiluje o 0,81 %. V rámci sektorů se nejvíce daří finančnímu sektoru (+1,35 %), průmyslu (+1,18 %) a nezbytné spotřebě (+1,15 %). Naopak ztrácí pouze sektor energetiky (-0,97 %).
Index DAX +1,36 % na 25099 b. Nejsilnější akcie Změna Nejslabší akcie Změna SAP (SAP) +9,3 % Volkswagen (VOW3) -2,0 % Siemens Healthineers (SHL) +3,0 % Infineon Technologies (IFX) -1,7 % Fresenius (FRE) +2,2 % Adidas (ADS) -1,6 % Deutsche Bank (DBK) +2,1 % Brenntag (BNR) -0,7 % Rheinmetall AG (RHM) +2,0 % Qiagen (QIA) -0,7 %
Zdroj: Bloomberg
Německý index DAX otevírá úterní obchodování v mírně kladných hodnotách. Růst o 1,7 % si připisují akcie Daimler Truck Holding, když analytik z Kepler Cheuvreux změnil investiční doporučení z „reduce“ na „buy“.
Index DAX +0,12 % na 24876,12 b. Nejsilnější akcie Změna Nejslabší akcie Změna Infineon Technologies (IFX) +2,2 % Qiagen (QIA) -2,0 % Daimler Truck Holding AG (DTG) +1,7 % Siemens Healthineers (SHL) -1,7 % Rheinmetall AG (RHM) +1,2 % Scout24 SE (G24) -1,3 % Deutsche Post AG (DHL) +1,0 % Merck (MRK) -1,1 % Fresenius Medical Care (FME) +0,9 % Brenntag (BNR) -0,9 % Zdroj: Bloomberg
Jakub Němec
Fio banka, a.s.
Prohlášení
Související odkazy DAX uzavírá čtvrtek v záporu, Rheimetall reportoval kvartální čísla Shrnutí kvartálních výsledků z indexu DAX Frankfurtská burza v úvodu čtvrtečního obchodování mírně posiluje Frankfurtská burza druhou seanci v řadě posílila, Daimler Truck vybuduje v Chebu nový závod Frankfurtská burza otevírá seanci v záporném teritoriu
Allspring Global Investments Holdings LLC lessened its holdings in shares of Qiagen N.V. (NYSE:QGEN – Free Report) by 21.6% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 2,481,645 shares of the company’s stock after selling 683,160 shares during the period. Allspring Global Investments Holdings LLC owned 1.20% of Qiagen worth $100,209,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in QGEN. Danske Bank A S acquired a new position in shares of Qiagen during the third quarter worth approximately $36,000. Manchester Capital Management LLC bought a new stake in shares of Qiagen during the fourth quarter worth $42,000. Global Retirement Partners LLC increased its position in Qiagen by 279.9% in the fourth quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock worth $52,000 after purchasing an additional 851 shares during the period. Allworth Financial LP raised its holdings in Qiagen by 23.2% during the 3rd quarter. Allworth Financial LP now owns 1,358 shares of the company’s stock worth $61,000 after purchasing an additional 256 shares during the last quarter. Finally, Advisory Services Network LLC bought a new stake in Qiagen during the 3rd quarter worth about $64,000. 70.00% of the stock is currently owned by institutional investors and hedge funds.
Qiagen Stock Down 0.8% QGEN stock opened at $41.19 on Friday. Qiagen N.V. has a 1-year low of $32.53 and a 1-year high of $57.81. The business’s 50 day simple moving average is $37.34 and its 200 day simple moving average is $42.37. The company has a current ratio of 3.21, a quick ratio of 2.57 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $8.49 billion, a PE ratio of 21.51, a PEG ratio of 4.14 and a beta of 0.64.
Qiagen (NYSE:QGEN – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.54 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.54. The business had revenue of $492.32 million during the quarter, compared to the consensus estimate of $496.15 million. Qiagen had a return on equity of 14.40% and a net margin of 19.16%.During the same quarter last year, the firm posted $0.56 EPS. As a group, research analysts anticipate that Qiagen N.V. will post 2.43 EPS for the current year.
Qiagen Increases Dividend The company also recently announced an annual dividend, which was paid on Tuesday, July 14th. Stockholders of record on Tuesday, July 7th were paid a dividend of $0.35 per share. This represents a dividend yield of 90.0%. This is an increase from Qiagen’s previous annual dividend of $0.26. The ex-dividend date was Tuesday, July 7th. Qiagen’s dividend payout ratio is 18.32%.
Analyst Ratings Changes Several equities research analysts have recently commented on QGEN shares. Berenberg Bank set a $45.50 price target on shares of Qiagen and gave the stock a “hold” rating in a research report on Tuesday. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $43.00 price objective on shares of Qiagen in a report on Thursday, April 30th. Wall Street Zen lowered shares of Qiagen from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Barclays set a $38.00 target price on shares of Qiagen and gave the company an “equal weight” rating in a research report on Wednesday, April 29th. Finally, Citigroup reissued a “hold” rating on shares of Qiagen in a research note on Monday, May 18th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Qiagen currently has an average rating of “Hold” and a consensus price target of $43.34.
Get Our Latest Stock Report on QGEN
Qiagen Company Profile (Free Report)
Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.
The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.
Featured Stories Five stocks we like better than Qiagen AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident GE Aerospace Faces a Prove-It Moment in Q2 Earnings Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen N.V. (NYSE:QGEN – Free Report).
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEAlamos Gold Inc. $AGI Shares Purchased by Allspring Global Investments Holdings LLC
NEXT HEADLINE »Capital One Financial Corporation $COF Shares Bought by Allspring Global Investments Holdings LLC
GERMANTOWN, Md., & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis cases reported across the United States.
More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May, along with another 7,000 potential cases, as health authorities investigate multiple outbreaks involving Cyclospora cayetanensis, a foodborne parasite that can cause prolonged diarrhea and other gastrointestinal symptoms. The parasite is not detected through routine stool culture and requires specialized diagnostic methods, including molecular testing.
QIAGEN's Sample to Insight portfolio supports laboratories across the molecular testing continuum, from syndromic diagnostics and digital PCR to next-generation sequencing (NGS):
The FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 includes Cyclospora cayetanensis as a standard target within its 16-target menu for bacterial, viral and parasitic pathogens. The fully integrated syndromic test delivers results in about an hour, enabling laboratories to test for Cyclospora alongside other common causes of gastrointestinal illness from the initial patient sample. For research use only, QIAGEN offers the digital PCR Microbial DNA Detection Assay targeting Cyclospora cayetanensis for use with the QIAcuity digital PCR system, supporting highly sensitive detection in research and public health applications. QIAGEN's sequencing portfolio also includes the PulseNet-approved QIAseq FX DNA Library Prep Kit for research use only with any NGS sequencer. This kit is designed to support “shotgun sequencing workflows” that analyze all DNA in a sample to help identify and characterize foodborne pathogens for PulseNet, the U.S. public health laboratory network that detects and investigates foodborne disease outbreaks. “The current rise in cyclosporiasis cases highlights the need for rapid, reliable detection to support timely patient care and effective public health action,” said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. “QIAGEN is ready to support laboratories and public health authorities worldwide with molecular testing technologies that help detect infections, guide investigations and strengthen responses to emerging disease threats.”
Further information about QIAGEN's molecular testing solutions supporting clinical diagnostics, research and public health laboratories is available through local QIAGEN representatives or the QIAGEN Customer Care team on www.qiagen.com.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of June 30, 2026, QIAGEN employed approximately 5,500 people across more than 35 locations. For more information, visit www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2026. Press release date / time: Wednesday, August 5 shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, August 6, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. Three options for joining the conference call Register for call back connection - Click her.
VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel, establishing a comprehensive bloodstream infection testing offering on the QIAstat-Dx platform in Europe.
The new QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance (AMR) markers from positive blood cultures in about one hour. It complements the recently launched QIAstat-Dx BCID GPF Plus AMR Panel in Europe, extending QIAGEN's bloodstream infection testing coverage across gram-positive bacteria, gram-negative bacteria, fungi and key AMR markers. Together, the two panels detect 33 pathogen targets and 28 AMR markers, enabling rapid identification of the most clinically relevant bloodstream pathogens and resistance mechanisms to support earlier pathogen identification and clinical decision-making.
“Every hour matters when treating bloodstream infections, particularly when AMR is involved,” said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. “Together, our complementary BCID panels provide comprehensive molecular coverage of the pathogens and resistance mechanisms most relevant to bloodstream infections. By delivering results in about one hour, they help laboratories support faster treatment decisions, antimicrobial stewardship and effective infection control.”
Gram-negative pathogens are among the leading causes of bloodstream infections and are frequently associated with AMR, one of the world's most significant public health threats. AMR occurs when bacteria develop mechanisms that render antibiotics ineffective, making infections more difficult to treat and increasing the risk of severe illness and death. In bloodstream infections, delays in identifying resistant pathogens can postpone appropriate therapy, while the growing burden of beta-lactam resistance driven by extended-spectrum beta-lactamase (ESBL) and carbapenemase-producing organisms underscores the need for rapid and accurate detection. With broad coverage of key beta-lactam resistance mechanisms, the QIAstat-Dx BCID GN Plus AMR Panel provides rapid, actionable molecular insights to support optimized treatment decisions and infection control.
The QIAstat-Dx BCID GN Plus AMR Panel is CE-IVDR certified and available in applicable markets. Regulatory review by the U.S. Food and Drug Administration is underway.
QIAGEN's CE-IVDR-certified QIAstat-Dx menu in Europe spans key syndromic testing areas, including respiratory infections, gastrointestinal infections, central nervous system infections through its meningitis / encephalitis panel and bloodstream infection testing. With the addition of the BCID GN Plus AMR Panel, the QIAstat-Dx platform now provides comprehensive bloodstream infection testing through complementary gram-positive and gram-negative panels. Built around rapid, cartridge-based molecular testing, QIAstat-Dx integrates sample preparation, molecular analysis and result interpretation into a streamlined workflow, helping laboratories generate clinically relevant insights across a growing range of infectious disease applications.
QIAstat-Dx systems are available in more than 100 countries, with more than 5,200 instruments placed worldwide as of the end of 2025.
For more information about the QIAstat-Dx BCID GN Plus AMR Panel and the QIAstat-Dx system, visit https://www.qiagen.com/de-us/applications/syndromic-testing.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of March 31, 2026, QIAGEN employed approximately 5,500 people across more than 35 locations. For more information, visit www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Německé akcie, měřené indexem DAX, ve čtvrtek posílily o 0,87 %. Nejvíce rostly akcie Qiagen (+10,6 %), Infineon Technologies (+4,3 %) a Zalando (+3,4 %). Společnost Qiagen, zabývající se molekulárním testováním, podle informací osob obeznámených s problematikou přitahuje předběžný zájem o převzetí ze strany firem včetně EQT a Advent.
Naopak nejvíce oslabily akcie firem Rheinmetall (-4,3 %), Deutsche Boerse (-1,4 %) a Daimler Truck Holding (-1,3 %). Akcie evropských obranných společností klesaly poté, co summit NATO v Turecku přinesl nižší výdajové závazky, než investoři doufali, přičemž analytik Alessandro Pozzi z Mediobanca označil omezené zvýšení výdajů ve Španělsku a Itálii za poněkud zklamávající. Jens-Peter Rieck z mwb Research navíc snížil doporučení pro akcie Rheinmetall na stupeň „hold“ z původního „buy“ s tím, že pozemní systémy ztratily prioritu. Bulharská vláda navíc podle zpráv zpravodajského webu Mediapool s odvoláním na ministra hospodářství Alexandera Puleva možná nebude schopna zajistit financování společného projektu s firmou Rheinmetall na závod na výrobu prachové náplně a dělostřeleckých granátů standardu NATO.
Celoevropský index STOXX Europe 600 si připisuje 0,76 %. Z jednotlivých sektorů vykazují největší růst informační technologie (+4,15 %), materiály (+1,35 %) a finance (+1,30 %). Naopak v záporném teritoriu se pohybují sektory energií (-1,11 %), zdravotní péče (-1,09 %) a nezbytného spotřebního zboží (-0,98 %).
Index DAX +0,87 % na 25114,37 b. Nejsilnější akcie Změna Nejslabší akcie Změna Qiagen (QIA) +10,6 % Rheinmetall AG (RHM) -4,3 % Infineon Technologies (IFX) +4,3 % Deutsche Boerse (DB1) -1,4 % Zalando (ZAL) +3,4 % Daimler Truck Holding AG (DTG) -1,3 % Siemens (SIE) +3,1 % Volkswagen (VOW3) -1,2 % Siemens Energy (ENR) +2,9 % Munich Re (MUV2) -1,2 % Zdroj: Bloomberg
Německé akcie měřené indexem DAX (+0,78 %) zakončily poslední seanci toho týdne v zelených číslech.
Z jednotlivých titulů byl v pozornosti investorů Siemens poté, co Kepler Cheuvreux zvýšil doporučení na „hold“ z „reduce“ a cílovou cenu zvýšil na 280 EUR z předchozích 255 EUR. Analytik William Mackie změnu zdůvodnil oceněním akcie před výsledky za 3Q, které Siemens zveřejní 6. srpna. Akcie Siemens připsaly 2,6 %. Analytici z Morgan Stanley zároveň navýšili cílovou cenu akcií E.ON na 22 EUR z 21,50 EUR a ponechali doporučení „overweight“. Banka očekává v aktuální výsledkové sezoně u utilit převážně pozitivní výsledky. Akcie E.ON +4,4 %.
Rheinmetall vyčíslil dopad zrušení německého námořního kontraktu na šest protiponorkových lodí F126 až na 300 mil. EUR tržeb v roce 2026. Analytička Marie-Ange Riggio z Morgan Stanley označila aktualizaci za uklidňující, protože firma nadále čeká meziroční růst tržeb přes 60 %. Banka JPMorgan naopak snížila cílovou cenu na 1350 EUR z 1500 EUR a upozornila na vyšší realizační rizika, přesto Rheinmetall dál vnímá jako nejrychleji rostoucí obrannou firmu ve svém pokrytí. Akcie společnosti Rheinmetall odepsaly 1,9 %.
Evropský index STOXX 600 se pohybuje v kladném teritoriu a posiluje o 0,71 %. V rámci sektorů se nejvíce daří IT (+2,38 %), utilitám (+1,69 %) a průmyslu (+1,37 %). Naopak největší ztráty zaznamenává nezbytná spotřeba (-0,20 %), zdravotnictví (-0,17 %) a zbytná spotřeba společně s realitami shodně (-0,02 %).
Index DAX +0,78 % na 25779,31 b. Nejsilnější akcie Změna Nejslabší akcie Změna E.ON (EOAN) +4,4 % Scout24 SE (G24) -2,0 % HOCHTIEF AG (HOT) +2,7 % Rheinmetall AG (RHM) -1,9 % Siemens (SIE) +2,6 % SAP (SAP) -1,5 % GEA Group AG (G1A) +2,3 % Merck (MRK) -1,3 % Daimler Truck Holding AG (DTG) +2,2 % Qiagen (QIA) -1,0 %
Zdroj: Bloomberg
Německé akcie měřené indexem DAX otevírají poslední seanci týden pozitivně naladěny.
Airbus se spolu s dalšími investory podílel na investičním kole ve výši 1,2 mld. USD pro německou obranně-technologickou firmu Quantum Systems. Firma chce peníze využít na rozvoj a dodávky autonomních systémů poháněných umělou inteligencí pro vzduch, zemi i moře. Transakce ocenila Quantum Systems na 8 mld. USD po započtení nové investice. Vedle Airbusu investici vedly také Blackstone, Noteus a Advent. Akcie Airbus +2 %.
RBC Capital Markets zvýšila investiční doporučení pro GEA Group na „outperform“ a stanovila cílovou cenu 70 EUR. Akcie GEA Group +2,2 %.
Index DAX +0,84 % na 25795,08 b. Nejsilnější akcie Změna Nejslabší akcie Změna HeidelbergCement (HEI) +2,5 % Rheinmetall AG (RHM) -1,2 % GEA Group AG (G1A) +2,2 % SAP (SAP) -1,0 % Deutsche Bank (DBK) +2,1 % Scout24 SE (G24) -0,9 % Airbus (AIR) +2,0 % Fresenius Medical Care (FME) -0,8 % E.ON (EOAN) +2,0 % Qiagen (QIA) -0,7 %
Zdroj: Bloomberg
Marek Krejčiřík
Fio banka, a.s.
Prohlášení
Související odkazy Německé akcie uprostřed týdne mírně posílily Frankfurtská burza otevírá druhé pololetí nepatrným růstem Německé akcie klesly o téměř 1 % Frankfurtská burza na začátku obchodování mírně posiluje Frankfurtská burza uzavřela úterní seanci na zelené nule
Key Takeaways QIAGEN expanded its QIAcuity dPCR ecosystem with gene expression tools and automation.New QIAcuity assays and a multiplex PCR kit aim to reduce sample use and workflow complexity.QIAcuity has topped 3,200 placements worldwide and is cited in over 1,100 publications. QIAGEN (QGEN - Free Report) recently expanded its QIAcuity digital PCR (dPCR) ecosystem with new gene expression solutions, enhanced multiplexing capabilities, workflow automation and standardized analysis tools. The move is aimed at accelerating the adoption of dPCR across research and biopharma applications as customers increasingly seek higher sensitivity, precision and scalability beyond traditional qPCR technologies.
From an investor's perspective, the latest additions strengthen QIAGEN's position in the fast-growing digital PCR market and expand its reach into gene expression, one of molecular biology's largest application areas. The broader QIAcuity portfolio, combined with automation and cell and gene therapy capabilities, could support higher platform adoption and create new long-term growth opportunities for the company.
Likely Trend of QGEN Stock Following the NewsShares of QGEN have traded flat since the announcement of the news. In the year-to-date period, shares of the company have lost 21.7% compared with the industry’s 1.3% decline. The S&P 500 increased 8.1% in the same time frame.
The expansion of the QIAcuity ecosystem is expected to strengthen QIAGEN's long-term growth prospects by broadening the platform's applications across gene expression research, cell and gene therapy quality control and high-throughput biopharma workflows. The launch of new assays, enhanced multiplexing capabilities and workflow automation should drive higher instrument placements, increase recurring consumables demand and deepen customer engagement. As more laboratories transition from qPCR to dPCR technologies, QIAGEN is well-positioned to capture a larger share of the expanding digital PCR market and build a more durable, recurring revenue stream around the QIAcuity franchise.
QGEN currently has a market capitalization of $7.64 billion.
Image Source: Zacks Investment Research
More on the NewsAs part of the expansion, QIAGEN plans to launch new QIAcuity Gene Expression Assays later in 2026 to support gene expression analysis across human, mouse and rat research applications. The company also intends to introduce the QIAcuity OneStep High Multiplex Probe PCR Kit, which can analyze up to 12 RNA targets in a single reaction. The offering is expected to help researchers generate richer biological insights while reducing sample consumption, hands-on time and workflow complexity. These solutions complement QIAGEN's GeneGlobe platform, which provides access to more than 10 million predesigned assays and custom assay design capabilities.
QIAGEN is also broadening its Cell and Gene Therapy quality-control portfolio by expanding its residual DNA testing offerings to support additional producer cell systems, including Sf9/Baculovirus, Pichia pastoris, Vero and Mouse. The portfolio further includes the recently launched QIAcuity HEK293 resDNA Sizing Kit, which enables precise measurement of host-cell DNA concentration and fragment size distribution, supporting biopharmaceutical development and manufacturing workflows.
Further, QIAGEN plans to release QIAcuity Software 3.5 later this month, introducing advanced analysis templates and automated reporting capabilities that allow laboratories to define analysis and reporting parameters before a run begins. By automatically applying analysis parameters and generating reports after run completion, the software is expected to improve traceability, consistency and operational efficiency, particularly in larger-scale and regulated environments.
Additionally, through its collaboration with Hamilton, QIAGEN is enabling automated QIAcuity dPCR nanoplate setup and handling workflows, spanning sample preparation, nanoplate filling and sealing. The company noted that QIAcuity has achieved more than 3,200 cumulative placements worldwide, with over 400 customers operating multiple instruments and more than 1,100 scientific publications referencing the platform.
Favorable Industry Prospect for QGENPer a report by Precedence Research, the global digital PCR market size was $7.78 billion in 2025 and is predicted to increase from $8.51 billion in 2026 to approximately $18.72 billion by 2035, expanding at a CAGR of 9.18%.
The market is driven by increasing demand for accurate and reliable nucleic acid testing in areas such as clinical diagnostics, research and development and biopharmaceuticals.
A Recent Development by QGENRecently, QIAGEN announced that its QIAstat-Dx Meningitis/Encephalitis Panel has been included in the Australian Register of Therapeutic Goods, expanding the company's molecular diagnostic offerings in Australia. The panel enables the detection of 16 common bacterial, viral and fungal pathogens, including cytomegalovirus and Streptococcus pyogenes, from a single cerebrospinal fluid sample using multiplex PCR technology. Delivering results in about one hour, the test supports rapid and accurate clinical decision-making in acute care settings and becomes the third QIAstat-Dx panel registered in Australia, alongside respiratory and gastrointestinal infection testing solutions.
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Globus Medical, currently flaunting a Zacks Rank #1 (Strong Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12 per share, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
West Pharmaceutical, currently sporting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.
WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
ISRG has a long-term estimated growth rate of 14.6% compared with the industry’s 12.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its QIAcuity digital PCR (dPCR) ecosystem, with a focus on expanding gene expression capabilities, broadening assay content and enhancing workflow standardization to support the growing adoption of dPCR across life sciences and biopharma applications.
As researchers increasingly seek higher sensitivity, greater precision and improved multiplexing capabilities, dPCR is gaining adoption across a growing range of applications traditionally served by qPCR technologies. QIAGEN is expanding the QIAcuity ecosystem with new gene expression solutions, workflow automation and analysis capabilities designed to support broader adoption of digital PCR across research and biopharma applications.
"Gene expression represents one of the largest application areas in molecular biology and a significant opportunity for digital PCR," said Thierry Bernard, CEO of QIAGEN. "By expanding the QIAcuity ecosystem with new assays, enhanced multiplexing capabilities and workflow solutions, we are helping customers apply digital PCR to a broader range of research and biopharma applications."
The latest additions to the QIAcuity portfolio include:
New gene expression solutions for dPCR: QIAGEN plans to expand its portfolio later in 2026 with new QIAcuity Gene Expression Assays designed to support gene expression analysis across human, mouse and rat research applications. The company also plans to introduce the new QIAcuity OneStep High Multiplex Probe PCR Kit, enabling analysis of up to 12 RNA targets in a single reaction and helping researchers generate richer biological insights while reducing sample consumption, hands-on time and workflow complexity. These additions complement QIAGEN's GeneGlobe platform, providing access to more than 10 million predesigned assays as well as custom assay design capabilities for specialized research needs. Expanded Cell and Gene Therapy quality control portfolio: Building on its established portfolio of dPCR solutions for Cell and Gene Therapy applications, QIAGEN is expanding its residual DNA testing offering to support additional producer cell systems, including Sf9/Baculovirus, Pichia pastoris, Vero and Mouse. The portfolio also includes the recently launched QIAcuity HEK293 resDNA Sizing Kit, which enables precise measurement of both host-cell DNA concentration and fragment size distribution to support biopharmaceutical development and manufacturing workflows. Enhanced automated analysis and reporting with QIAcuity Software 3.5: Scheduled for release later this month, QIAcuity Software 3.5 introduces advanced analysis templates and automated reporting capabilities that enable users to define analysis and reporting parameters before a run begins. The software helps laboratories automate and standardize data interpretation and reporting through predefined analysis and reporting templates. By automatically applying analysis parameters and generating reports after run completion, laboratories can reduce manual review steps while improving traceability, consistency and operational efficiency, particularly in larger-scale and regulated workflows. Expanded laboratory automation through Hamilton integration: In addition to the automated analysis and reporting capabilities introduced with QIAcuity Software 3.5, customers can build on QIAGEN's collaboration with Hamilton to automate QIAcuity dPCR nanoplate setup and handling workflows, including sample preparation, nanoplate filling and sealing. Integration with robotic systems enables fully automated workflows from assay setup through data analysis, helping high-throughput laboratories increase productivity while minimizing risks associated with manual handling. QIAcuity adoption continues to grow across academia, biopharma and clinical research, with over 3,200 cumulative placements worldwide since launch. More than 400 customers now operate multiple QIAcuity instruments, while over 1,100 scientific publications reference the platform. The continued expansion of the QIAcuity ecosystem reflects QIAGEN's strategy to support customers throughout the transition from qPCR to dPCR and toward increasingly scalable, automated and standardized dPCR workflows.
Additional details on QIAGEN's QIAcuity dPCR strategy, technology roadmap and growth opportunities will be discussed during the upcoming QIAcuity Deep Dive event on Monday, June 15, 2026. The event will be webcast and available to investors, analysts and other interested stakeholders. More information is available at https://corporate.qiagen.com/English/investor-relations/events-and-presentations/QIAGEN-Deep-Dive--QIAcuity-digital-PCR/default.aspx.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of March 31, 2026, QIAGEN employed approximately 5,500 people across more than 35 locations. For more information, visit www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.
VENLO, Netherlands & REDWOOD CITY, Calif.--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced at the 2026 BIO-IT World Conference & Expo in Boston that the QIAGEN Digital Insights bioinformatics business and its curated knowledge bases and bioinformatics expertise will be integrating NVIDIA accelerated computing and the NVIDIA BioNeMo platform to help researchers use AI more effectively in drug discovery.
The integration is designed to help pharmaceutical and biotechnology researchers better understand disease biology, identify promising therapeutic targets and uncover biomarkers that can support faster and more effective development of new medicines.
Drug discovery depends on connecting large amounts of complex biological information, including genes, diseases, pathways, compounds and clinical evidence. For many research teams, the challenge is finding the most relevant connections amid increasing amounts of data to understand why they matter and assess whether an AI-generated insight is supported by credible biology.
QIAGEN and NVIDIA are working to address this challenge through graph-based AI. This approach applies retrieval and reasoning techniques over biomedical knowledge graphs, allowing researchers to explore evidence across biological systems and supporting a path toward agentic, multi-step workflows for drug discovery.
“QIAGEN Digital Insights has spent more than 25 years building the biomedical knowledge foundation that researchers rely on to interpret complex biology,” said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. “Through this collaboration with NVIDIA, we can accelerate the impact of that knowledge by combining it with advanced AI to help customers improve critical steps in drug discovery, from target identification to biomarker research and hypothesis generation.”
The collaboration is designed to support practical applications across the drug discovery lifecycle, including target identification and validation, drug repurposing, biomarker discovery, pathway analysis and hypothesis generation from multi-omics data. By combining curated biomedical knowledge, graph-based AI and accelerated computing, QIAGEN aims to help research teams move from complex data to better-informed discovery decisions.
Initial pilot programs will be made available to select pharmaceutical and biotechnology partners, with broader availability of these new solutions expected following validation.
QIAGEN Digital Insights is developing a range of new AI-enhanced solutions designed to help life sciences organizations extract more value from complex biological, clinical and molecular data.
These solutions build on more than 25 years of curated biomedical knowledge, including knowledge bases used by more than 150,000 scientists worldwide and supported by more than 70,000 scientific publications. By organizing evidence across genes, diseases, pathways, compounds, clinical insights and more than 30,000 diseases, QIAGEN Digital Insights provides the scientific context needed to help researchers assess whether AI-generated insights are biologically credible, novel and relevant to drug discovery.
QIAGEN's Discovery Platform integrates curated information across genes, diseases, pathways, compounds and clinical insights. To support AI-driven querying across this knowledge graph, the platform is designed to incorporate graph-based retrieval AI drawing on frameworks such as PyTorch Geometric and GPU accelerated GraphRAG systems, with delivery through the NVIDIA BioNeMo platform. This will enable researchers to ask natural language questions across biomedical knowledge graphs while retaining a clear link to structured scientific evidence.
To learn more about the pilot program or explore how the QIAGEN Discovery Platform can support your drug discovery workflows, visit https://digitalinsights.qiagen.com/qiagen-discovery-platform or contact [email protected].
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of March 31, 2026, QIAGEN employed approximately 5,500 people across more than 35 locations. For more information, visit www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. (“Qiagen” or the “Company”) (NYSE: QGEN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Qiagen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On April 27, 2026, Qiagen announced preliminary results for the first quarter of 2026. Among other items, the Company disclosed that net sales declined approximately 1% on a constant exchange rate (“CER”) basis, and that sales of its QuantiFERON product declined approximately 5% CER.
On this news, Qiagen’s stock price fell $4.07 per share, or 10.69%, to close at $34.02 per share on April 28, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Qiagen N.V. (“Qiagen” or the “Company”) (NYSE:QGEN) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
[LEARN MORE ABOUT THE INVESTIGATION]
What Happened?
On February 5, 2026, Qiagen released fourth quarter 2025 earnings and stated that QuantiFERON would accelerate to achieve “between 6% and 7% growth” in 2026.
On April 27, 2026, Qiagen announced preliminary results for the first quarter of 2026. Among other things, the Company disclosed that net sales declined approximately 1% on a constant exchange rate (“CER”) basis, and that sales of its QuantiFERON product declined approximately 5% CER. On this news, the price of Qiagen shares declined by $4.07 per share, or approximately 11%, from $38.09 per share on April 27, 2026 to close at $34.02 on April 28, 2026.
What Should I Do?
At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.
If you purchased or otherwise acquired Qiagen securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.
[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Qiagen shares dropped more than 10% after the company slashed FY 2026 sales-growth guidance from "at least 5% CER" to just 1-2% CER -- erasing hundreds of millions in market capitalization in a single session.
, /PRNewswire/ -- Shareholders of Qiagen N.V. (NASDAQ: QGEN) saw over 10% wiped from the stock's value after the company cut its full-year 2026 outlook, driven by a 5% CER decline in QuantiFERON TB test volumes during Q1 2026. Investors who lost money on QGEN are encouraged to submit their information to discuss their legal rights. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
The market reaction was swift and severe. Qiagen's revised outlook -- sales growth of approximately 1-2% CER and adjusted diluted EPS of at least $2.43 -- represented a sharp reduction from the February 5, 2026 guidance of "at least 5% CER" sales growth and adjusted diluted EPS of "at least $2.50 at CER." CFO Roland Sackers had projected on that same February call that QuantiFERON would deliver "about 6% CER growth" for the full year. Weeks later, Q1 2026 volumes showed a 5% CER decline year-over-year.
The speed and scale of the reversal caught the market off guard. Between the February 5 guidance and the subsequent cut, no public disclosure from Qiagen signaled that QuantiFERON demand was deteriorating at this pace. The approximately 10% single-session decline reflected the market repricing the company's growth trajectory in real time.
Shareholders who purchased QGEN and suffered losses may click here to get more information about this investigation. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
ABOUT THE FIRM -- For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years.
Frequently Asked Questions About the QGEN Investigation
Q: Who is eligible to participate in the QGEN investigation? A: Investors who recently acquired QGEN stock or securities and were impacted by the sharp decline in stock price on April 28, 2026.
Q: How much did QGEN stock drop? A: Shares fell more than 10% after Qiagen disclosed a material reduction in its FY 2026 sales-growth and EPS guidance, driven by weaker demand for its QuantiFERON TB test and immigration-related testing. Investors who purchased shares at artificially inflated prices may be entitled to compensation.
Q: What do QGEN investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible as a class member.
Q: What if I already sold my QGEN shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.
Q: Do I need to go to court or give testimony? A: No. This is currently just an investigation. Even if a suit is filed, however, the overwhelming majority of class members never appear in court or give depositions. You submit a claim form to receive your portion of recovery.
Q: What does it cost me to participate? A: Nothing. Securities investigations and the potential resultant class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.
Q: Has Levi & Korsinsky handled similar cases before? A: Yes, including securities class actions involving revenue inflation, earnings guidance fraud, dividend misrepresentation, and executive misconduct across numerous industries.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
Key Takeaways TSM will pay a $1.10 dividend on Oct. 8 and has raised payouts 15 times in five years.QGEN declared a $0.35 dividend for July 14, with a current dividend yield of 0.78%.AG announced a $0.02 dividend for May 29 and has increased payouts 12 times in five years. Volatility has returned to Wall Street, with the S&P 500 declining for the third straight session on Tuesday after hitting an all-time closing high last week. High inflation and surging oil prices owing to the ongoing Iran war have been weighing on the economy, with consumer confidence hitting rock bottom.
Also, concerns have been growing that the Federal Reserve could go for a rate hike as it struggles to control sky-high inflation.
Given the uncertainty, cautious investors looking for steady income and ways to protect their capital may consider holding or investing in dividend-paying stocks.
Such stocks provide steady earnings through regular dividend payouts and can help mitigate the effects of market volatility. Three such stocks are: Taiwan Semiconductor Manufacturing Company Limited (TSM - Free Report) , Qiagen N.V. (QGEN - Free Report) and First Majestic Silver Corp. (AG - Free Report) . Each of these stocks currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Concerns Grow Over EconomyTreasury yields have surged lately on reports that inflation has been on the rise as the Iran war has led to a surge in oil prices. On Tuesday, the yield on the 30-year Treasury briefly climbed above 5.19%, reaching its highest level in nearly 19 years.
Also, the 10-year Treasury note yield — a key benchmark for mortgage rates, auto loans, and credit card borrowing costs — jumped to 4.687%, its highest point since January 2025. The ongoing war with Iran has triggered a nearly 40% jump in oil prices, which has been weighing on the economy.
Inflation, which was steadily heading toward the Federal Reserve’s 2% target, has been on the rise over the past couple of months.
The latest inflation data showed that consumer prices continued to rise at a faster pace in April. According to the Bureau of Labor Statistics, the consumer price index (CPI) increased 0.6% from the previous month after climbing 0.9% in March. Compared with a year earlier, CPI was up 3.8% in April, marking its highest annual increase since May 2023.
Core CPI, which excludes the more volatile food and energy categories, also moved higher. It rose 0.4% month over month in April and was up 2.8% from the same period last year.
The recent surge in inflation has complicated the Federal Reserve’s plans for interest rate cuts. While the central bank had paused rate cuts this year and previously signaled the possibility of cuts later in 2026, the stronger-than-expected inflation readings over the past two months have made that outlook far more uncertain. As inflation pressures persist, expectations for near-term rate cuts have weakened significantly.
3 Stocks That Recently Announced Dividend HikesTaiwan Semiconductor Manufacturing Company LimitedTaiwan Semiconductor Manufacturing Company Limited is the world's largest dedicated integrated circuit foundry. TSM manufactures ICs for its customers based on their proprietary IC designs using its advanced production processes.
On May 12, Taiwan Semiconductor Manufacturing Company Limited announced that its shareholders would receive a dividend of $1.10 a share on Oct. 8. TSM has a dividend yield of 0.75%. Over the past five years, Taiwan Semiconductor Manufacturing Company Limited has increased its dividend 15 times, and its payout ratio presently sits at 25% of earnings. Check Taiwan Semiconductor Manufacturing Company Limited’s dividend history here.
Qiagen N.V.
Qiagen N.V. is one of the world’s leading providers of technologies and products for the separation, purification and handling of nucleic acids, DNA/RNA. QGEN provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions.
On May 11, Qiagen declared that its shareholders would receive a dividend of $0.35 a share on July 14. QGEN has a dividend yield of 0.78%. Over the past five years, Qiagen has increased its dividend once, and its payout ratio presently sits at 11% of earnings. Check Qiagen’s dividend history here.
First Majestic Silver Corp.First Majestic Silver Corp. is engaged in the production, development, exploration and acquisition of silver mines in Mexico.
On May 11, First Majestic Silver announced that its shareholders would receive a dividend of $0.02 a share on May 29. AG has a dividend yield of 0.17%. Over the past five years, First Majestic Silver has increased its dividend 12 times, and its payout ratio presently sits at 5% of earnings. Check First Majestic Silver Corp’s dividend history here.
VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the global launch of QIA Agent, an AI-powered digital assistant designed to simplify how researchers plan experiments, identify suitable products, access technical information and manage ordering support through a single conversational interface.
“Researchers today are navigating growing scientific complexity, increasing volumes of data and expanding workflow choices,” said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. “QIA Agent is designed to simplify how researchers interact with scientific information, workflow guidance and operational support through a single AI-powered experience. By embedding conversational AI into our digital ecosystem, we aim to help customers move faster from questions to decisions across Sample to Insight workflows.”
As laboratories generate increasing amounts of data and workflows become more complex, researchers are seeking more intuitive ways to access scientific expertise, technical guidance and operational support. Conversational AI is emerging as a new interface layer for scientific workflows, helping reduce friction across research, purchasing and laboratory operations.
QIA Agent addresses these challenges by connecting QIAGEN’s product information, protocols, technical documentation, ordering tools and support resources through a natural-language interface.
It is accessible with or without login, allowing users to engage immediately while offering a more personalized experience when signed in. Logged-in users can access individual pricing, order history and account-specific information, making interactions more relevant and efficient. With more than 260,000 users already registered on “My QIAGEN” at www.qiagen.com, the platform builds on an established digital customer base.
Key features and benefits include:
Natural-language scientific guidance: Researchers can interact with QIA Agent through a conversational interface and receive guidance linked to relevant QIAGEN products, protocols, technical information and recommended next steps. Connected product and workflow intelligence: QIA Agent combines product information, protocols, technical documentation and support resources to support decision-making for experiment planning and product selection. Integration with QIAGEN digital services: The platform connects researchers with existing QIAGEN tools, including the Experiment Configurator, Order Status Checker, Product Availability Checker and Help Center to create a seamless interface from experiment planning through post-purchase support. Ordering and support access in one place: Researchers can check product availability, track orders and access relevant support information without moving across multiple systems. Improved laboratory efficiency: By simplifying access to scientific information, digital tools and operational support, QIA Agent is designed to help laboratories save time, improve productivity through faster and more informed decisions. QIA Agent is now publicly accessible via www.qiagen.com to all QIAGEN customers worldwide. It is currently intended for research use and is not designed for diagnostic applications.
The launch of QIA Agent forms part of QIAGEN’s broader efforts to apply AI and digital technologies across its customer-facing ecosystem. By embedding AI-enabled assistance into laboratory workflows, QIAGEN aims to make scientific information, product selection and operational support easier to access for researchers worldwide.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of March 31, 2026, QIAGEN employed approximately 5,500 people across more than 35 locations. For more information, visit www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.
Key Takeaways QIAGEN launched QIA Agent to simplify experiment planning and product support workflows.QGEN's AI platform connects research tools, protocols and ordering support in one interface.QIAGEN said QIA Agent can improve lab productivity and accelerate scientific decisions. QIAGEN (QGEN - Free Report) recently launched QIA Agent, an AI-powered digital assistant designed to simplify how researchers plan experiments, identify products, access technical information and manage ordering support through a single conversational interface.
Management noted that QIA Agent expands the company’s broader AI-enabled digital ecosystem strategy by embedding conversational AI directly into customer workflows. The launch is expected to strengthen customer engagement and improve workflow efficiency across laboratories worldwide.
Likely Trend of QGEN Stock Following the NewsShares of QGEN have gained 2.5% since the announcement on Wednesday. In the year-to-date period, shares of the company have lost 25.9% compared with the industry’s 2.8% decline. However, the S&P 500 has risen 8.1% during the same timeframe.
The launch of QIA Agent is likely to strengthen QIAGEN’s long-term growth prospects by deepening customer engagement across its Sample to Insight workflows and expanding its digital ecosystem capabilities. By integrating AI-driven scientific guidance, product discovery and operational support into a single conversational platform, QIAGEN can improve customer retention, increase cross-selling opportunities and drive higher utilization of its consumables and workflow solutions.
The platform also positions the company to capitalize on the growing adoption of AI-enabled laboratory workflows, while enhancing operational efficiency and differentiating QIAGEN’s offerings in the competitive life sciences tools market.
QGEN currently has a market capitalization of $7.06 billion.
Image Source: Zacks Investment Research
More on the QGEN’s QIA AgentQIA Agent platform connects multiple elements of QIAGEN’s Sample to Insight ecosystem through a single conversational interface, enabling researchers to plan experiments, identify suitable products, access technical documentation and manage ordering-related tasks more efficiently. The company noted that QIA Agent is accessible directly through its website and can be used both with and without login credentials, allowing broader access while offering more personalized experiences for registered users.
Management highlighted that the launch comes at a time when laboratories are dealing with increasing scientific complexity, expanding workflow choices and rapidly growing data volumes. QIA Agent leverages conversational AI to help reduce the time researchers spend searching across multiple systems and resources. The platform combines product information, protocols, technical documentation and support tools into one integrated interface, enabling quicker and more informed decision-making. Logged-in users can additionally access account-specific information, including pricing, order history and customized support, helping improve convenience and workflow continuity. The company currently has more than 260,000 registered users on its My QIAGEN platform, providing an established customer base for adoption of the new AI-driven tool.
The platform also integrates with several existing QIAGEN digital services, including the Experiment Configurator, Order Status Checker, Product Availability Checker and Help Center, creating a more seamless experience from experiment planning to post-purchase support. Researchers can use QIA Agent to check product availability, track orders and access workflow guidance without switching between multiple systems.
Per management, the launch forms part of QIAGEN’s broader strategy to embed AI and digital technologies across its customer-facing ecosystem. While currently intended for research use only and not diagnostic applications, the company believes the platform can help laboratories improve productivity, save time and accelerate scientific decision-making through easier access to relevant information and workflow support.
Industry Prospects Favoring the MarketPer a report by Grand View Research, the global artificial intelligence in healthcare market size was estimated at $36.67 billion in 2025 and is projected to reach $505.59 billion by 2033, expanding at a CAGR of 38.90%.
The key factor driving market growth is the increasing demand in the healthcare sector for enhanced efficiency, accuracy and better patient outcomes.
Other NewsQIAGEN recently announced a collaboration with NVIDIA to advance AI-driven drug discovery by integrating the latter’s accelerated computing and BioNeMo platform with QIAGEN Digital Insights’ curated biomedical knowledge bases. Management noted that the collaboration will initially support pilot programs with select pharmaceutical and biotechnology partners before broader commercial availability in future stages following validation.
Also, QGEN recently announced plans to launch a new fully automated Sample to Insight workflow and an AI-enabled risk stratification tool to advance QuantiFERON latent tuberculosis testing, with both targeted for launch in late 2027. The company also plans to introduce an AI-enabled risk stratification tool designed to support clinical decision-making by helping identify patients at higher risk of TB progression.
Some better-ranked stocks from the same medical industry are Pacific Biosciences of California (PACB - Free Report) , Globus Medical (GMED - Free Report) and Biodesix (BDSX - Free Report) .
Pacific Biosciences of California, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted loss per share of 12 cents, which surpassed the Zacks Consensus Estimate by 29.4%. Revenues of $37 million missed the Zacks Consensus Estimate by 9.3%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
PACB’s earnings are estimated to decline at a rate of 12.2% against the industry’s 16.9% growth in 2027. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 29.76%.
Globus Medical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted earnings per share of $1.12, which outpaced the Zacks Consensus Estimate by 21.7%. Revenues of $760 million surpassed the Zacks Consensus Estimate by 4%.
GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% rise. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 26.26%.
Biodesix, currently carrying a Zacks Rank of 2, reported a first-quarter 2026 adjusted loss per share of 81 cents, which beat the Zacks Consensus Estimate by 35.71%. Revenues of $26 million beat the Zacks Consensus Estimate by 12.3%.
BDSX has an estimated earnings growth rate of 36% for 2026 compared with the industry’s 13.4% rise. The company beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 25.56%.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. ("Qiagen" or the "Company") (NYSE: QGEN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Qiagen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On April 27, 2026, Qiagen announced preliminary results for the first quarter of 2026. Among other items, the Company disclosed that net sales declined approximately 1% on a constant exchange rate ("CER") basis, and that sales of its QuantiFERON product declined approximately 5% CER.
On this news, Qiagen's stock price fell $4.07 per share, or 10.69%, to close at $34.02 per share on April 28, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Qiagen N.V. (“Qiagen” or the “Company”) (NYSE:QGEN) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
[LEARN MORE ABOUT THE INVESTIGATION]
What Happened?
On February 5, 2026, Qiagen released fourth quarter 2025 earnings and stated that QuantiFERON would accelerate to achieve “between 6% and 7% growth” in 2026.
On April 27, 2026, Qiagen announced preliminary results for the first quarter of 2026. Among other things, the Company disclosed that net sales declined approximately 1% on a constant exchange rate (“CER”) basis, and that sales of its QuantiFERON product declined approximately 5% CER. On this news, the price of Qiagen shares declined by $4.07 per share, or approximately 11%, from $38.09 per share on April 27, 2026 to close at $34.02 on April 28, 2026.
What Should I Do?
At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.
If you purchased or otherwise acquired Qiagen securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.
[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. (“Qiagen” or the “Company”) (NYSE: QGEN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Qiagen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On April 27, 2026, Qiagen announced preliminary results for the first quarter of 2026. Among other items, the Company disclosed that net sales declined approximately 1% on a constant exchange rate (“CER”) basis, and that sales of its QuantiFERON product declined approximately 5% CER.
On this news, Qiagen’s stock price fell $4.07 per share, or 10.69%, to close at $34.02 per share on April 28, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. ("Qiagen" or the "Company") (NYSE: QGEN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Qiagen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On April 27, 2026, Qiagen announced preliminary results for the first quarter of 2026. Among other items, the Company disclosed that net sales declined approximately 1% on a constant exchange rate ("CER") basis, and that sales of its QuantiFERON product declined approximately 5% CER.
On this news, Qiagen's stock price fell $4.07 per share, or 10.69%, to close at $34.02 per share on April 28, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
Key Takeaways QIAGEN spans sample prep to molecular diagnostics with 500 consumables and automated workflows. QIAGEN says new launches could add ~2 pts of sales growth in 2H 2026, led by Connect systems.QIAGEN trimmed 2026 outlook to ~1-2% CER growth on tariffs, FX, and softer immigration testing. QIAGEN (QGEN - Free Report) has built a broad assay and biomarker portfolio that spans pre-analytical sample preparation and molecular diagnostics. That mix gives the company multiple shots on goal across clinical testing and life science workflows, even as spending patterns remain choppy.
The near-term setup is not uniform across end markets, but QIAGEN has shown it can protect profitability while continuing to fund targeted growth initiatives. Its Zacks Rank is #3 (Hold).
In the past year, QIAGEN’s shares have plunged roughly 23.7% against the industry’s growth of 18.7%.
Image Source: Zacks Investment Research
QGEN’s Portfolio Maps to Multiple Testing Growth AreasQIAGEN positions itself as a provider of technologies for the separation, purification, and handling of DNA and RNA, with offerings that start at sample collection and preparation and extend into molecular diagnostics. The company has developed a portfolio of more than 500 proprietary consumable products, alongside automated solutions designed to support standardized workflows.
The strategic thread running through the portfolio is breadth of content, then expansion of that content over time. Management continues to emphasize expanding test menus and improving automation-driven workflows to keep platforms relevant as labs seek faster and more repeatable processes.
The company has also highlighted collaborations and commercial partnerships as a way to broaden distribution and accelerate assay development, particularly in companion diagnostics, where adopted content can translate into recurring consumables once testing becomes standardized.
QIAGEN’s Revenue Mix Shows Where Demand Is ConcentratedQIAGEN organizes its business into two main product buckets. Consumables and related revenues include consumable kits, bioinformatics solutions, royalties, co-development milestone payments, and services. Instruments and related services include instruments, services, and contracts.
Within that structure, the 2024 portfolio-area mix shows where demand is concentrated. Diagnostic Solutions represented 37.9% of sales, Sample Technologies 32.5%, PCR and Nucleic Acid Amplification 15.2%, Genomics and Next-Generation Sequencing 11.8%, and Other 2.7%.
Each portfolio area bundles distinct platforms and use cases. Diagnostic Solutions includes molecular testing platforms and consumables such as QuantiFERON, QIAstat-Dx, and NeuMoDx, alongside Precision Diagnostics. Sample Technologies covers consumables and instruments used in sample collection, stabilization, storage, purification, and quality control. PCR and Nucleic Acid Amplification includes research and applied polymerase chain reaction solutions and components, including QIAcuity. Genomics and Next-Generation Sequencing includes universal next-generation sequencing solutions and the full QIAGEN Digital Insights portfolio.
Estimates for QGEN Heading SouthThe Zacks Consensus Estimate for QIAGEN’s 2026 sales and EPS implies a year-over-year improvement of 4.1% and 2.5%, respectively. The bottom-line estimates have moved southward in the past 30 days.
Image Source: Zacks Investment Research
QIAGEN’s 2026–2027 Growth View and What It ImpliesThe Zacks model points to steady growth, even if the path is not linear. QIAGEN’s revenues are modeled to deliver a compound annual growth rate of 5.9% through 2027. Diagnostic Solutions is expected to grow 1.9% year over year in 2026, while Genomics and Next-Generation Sequencing is expected to grow 3.3% in 2026.
Operationally, the levers behind that outlook tie back to content and workflow. QIAGEN continues to invest in research and development to expand menus and improve throughput across core platforms, including new gastrointestinal panel clearances on the QIAstat-Dx Rise system and continued advancement of additional panels. Management has also pointed to sample preparation automation, including rollout activity for new Connect systems, and expects new launches to contribute about two percentage points of sales growth in the second half of 2026.
QGEN’s Key Watch Items Investors Should TrackA primary checkpoint is whether second-half 2026 delivers the expected acceleration to roughly 4% sales growth at constant exchange rates, supported by new product launches, sequential improvement in QuantiFERON, and contributions from Parse as it tracks toward a 2026 sales target of $40 million.
Investors should also monitor traction from new launches, including the new Connect systems, and whether added platform content keeps translating into higher utilization and consumables pull-through as labs consolidate testing onto scalable workflows.
Finally, the external environment matters. Management has cited tariffs and currency movements as headwinds that pressured profitability in the first quarter, and it reduced the full-year 2026 outlook to roughly 1% to 2% growth at constant exchange rates amid softer immigration testing volumes and continued caution from U.S. Life Sciences customers. Competitive intensity remains high across the company’s markets, with peers in the same industry group including Thermo Fisher Scientific (TMO - Free Report) and Illumina (ILMN - Free Report) , which can raise the bar for winning budgeted placements when customers stay cautious.
You can see the complete list of today’s Zacks Rank #1 (Strong Buy) stocks here.
VENLO, Netherlands, & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the availability of two custom-designed research-use-only (RUO) digital PCR assays to support infectious disease research and surveillance efforts related to the Bundibugyo ebolavirus outbreak.
The assays are designed for use with the QIAcuity digital PCR system and are intended to help qualified laboratories evaluate emerging pathogen targets in research, wastewater surveillance and other environmental monitoring settings. They were developed using publicly available genomic sequence information released during the outbreak response and are part of QIAGEN’s broader Sample to Insight portfolio supporting infectious disease research workflows.
The assays target the nucleoprotein (NP) and VP35 regions of the virus. Initial in silico sequence analysis showed no mismatches against the currently published outbreak sequences reviewed by QIAGEN.
The assays are intended for research use only and are not intended for diagnostic procedures.
The availability of these assays underscores the role of adaptable molecular technologies in supporting public health research infrastructure. As genomic information from emerging infectious disease events becomes available, laboratories need flexible tools that can be evaluated and incorporated into existing research, surveillance and environmental monitoring workflows.
QIAGEN’s current portfolio supporting this infectious disease outbreak includes:
Research-use-only digital PCR assays targeting the NP and VP35 regions of Bundibugyo ebolavirus are available through QIAGEN’s custom assay workflow on a make-to-order basis. QIAseq sequencing panels are available from stock for fast delivery. Existing sample preparation and molecular workflow kits are available from stock to support nucleic acid processing for downstream digital PCR and next-generation sequencing workflows to support wastewater surveillance and molecular research applications. “Public health preparedness depends on the ability of laboratories to evaluate emerging pathogen targets as reliable genomic information becomes available,” said Thierry Bernard, Chief Executive Officer of QIAGEN. “QIAGEN is committed to supporting customers around the world with adaptable molecular technologies that help strengthen infectious disease research and surveillance capacity. Our goal remains clear: no country should be left behind when new threats emerge.”
The QIAcuity digital PCR system supports sensitive nucleic acid detection and quantification across a range of research applications, including infectious disease research and environmental surveillance. Combined with QIAGEN’s broader Sample to Insight portfolio, the platform enables laboratories to rapidly adapt existing workflows as new pathogen targets emerge.
Further information about QIAcuity digital PCR solutions and custom assay workflows is available through local QIAGEN representatives or customer care team.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of March 31, 2026, QIAGEN employed approximately 5,500 people across more than 35 locations. For more information, visit www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.
Key Takeaways QIAGEN posted Q1 2026 EPS and revenue misses, with uneven demand across end markets. QGEN still showed 27.4% adj operating margin, $54M free cash flow, and $646.3M cash, no debt. QIAGEN shares are down 23.7% YTD; FX, tariffs, and slower testing and spending add risk. QIAGEN N.V. (QGEN - Free Report) is sending investors a mixed near-term message after first-quarter earnings miss and a reset to its 2026 growth outlook. The stock carries a Zacks Rank #3 (Hold), and the Style Scores tilt defensive rather than directional.
With a VGM Score of D, QGEN screens as “balanced at best” today, especially with Value stronger than Growth and Momentum. The question is whether the company’s profitability and liquidity can steady the story while demand visibility stays choppy.
QIAGEN’s Q1 Print and What Drove the MissFirst-quarter 2026 results pointed to uneven demand and modest execution pressure. Adjusted earnings were $0.54 per share, down 2% year over year, and the result missed the consensus estimate by 1.2%. On a GAAP basis, earnings were $0.33 per share versus $0.41 a year ago.
Revenue was $492 million, up 2% year over year on a reported basis but down 1% at constant exchange rates. The top line also fell short of expectations, missing by 0.8%. Together, the numbers suggest demand did not cooperate evenly across end markets, and the company did not fully offset that with upside elsewhere during the quarter.
Based on short-term price targets from 10 analysts, the average price target for QIAGEN’s is $41.80, representing a potential 15.69% upside from the last closing price.
Image Source: Zacks Investment Research
QIAGEN’s Offsets: Profitability, Cash Flow, and Balance SheetEven with softer demand signals, QIAGEN delivered financial stabilizers that can matter in a reset year. The adjusted operating income margin was 27.4% in the first quarter, reflecting sustained profitability despite targeted investments and headwinds from tariffs and currency movements.
Cash generation also remained constructive. Free cash flow was $54 million in the quarter, supporting ongoing investment needs, including systems and infrastructure initiatives.
The balance sheet adds another layer of flexibility. QIAGEN ended the quarter with $646.3 million in cash and cash equivalents and no current debt. That liquidity can help the company keep funding targeted launches and workflow improvements, even as tariffs and foreign-exchange movements continue to pressure profitability.
QGEN’s Valuation Framing vs. BenchmarksThe stock’s decline provides important context for the current debate. QIAGEN shares are down 23.7% year to date and also down 23.7% over the past 12 months.
On valuation, QGEN trades at about 3.4 times forward 12-month sales. That is above the Zacks sub-industry and sector comparisons, but below the S&P 500 multiple shown in the same benchmark set.
Image Source: Zacks Investment Research
The $38 price target is framed through a multiple-based approach. It reflects 3.5 times forward 12-month sales, essentially signaling modest upside from recent levels while keeping expectations constrained by the slower growth outlook.
QIAGEN’s Decision Checklist From the Report’s RisksFor investors weighing a buy-versus-hold stance, the downside checklist is clear. QIAGEN remains sensitive to macro conditions and demand fluctuations, including reduced QuantiFERON immigration testing volumes, cautious spending from U.S. Life Sciences customers, and uneven original equipment manufacturer ordering patterns.
Foreign-exchange exposure is another swing factor, given that more than half of revenue is generated outside the United States. Tariffs also pressured profitability in the first quarter, and those costs can complicate margin forecasting while the company continues investing behind launches.
Execution timing in partnerships matters, too. Companion diagnostics programs can deliver multi-year opportunity, but revenue recognition depends on partner timelines and commercial success. QIAGEN reported $115 million in remaining performance obligations tied to companion diagnostic co-development contracts, with roughly half expected over the next 12 to 18 months.
Finally, competitive intensity can lengthen sales cycles when lab budgets tighten. That dynamic is not unique to QIAGEN. Illumina, Inc. (ILMN - Free Report) is a major player in sequencing and array solutions used across genomics workflows, and spending cycles in that ecosystem can influence broader purchasing behavior. Thermo Fisher Scientific Inc. (TMO - Free Report) also spans a wide range of life sciences research tools and consumables, underscoring how well-funded competitors can pressure pricing and decision timelines in cautious environments.
You can see the complete list of today’s Zacks Rank #1 (Strong Buy) stocks here.
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. (“Qiagen” or the “Company”) (NYSE: QGEN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Qiagen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On April 27, 2026, Qiagen announced preliminary results for the first quarter of 2026. Among other items, the Company disclosed that net sales declined approximately 1% on a constant exchange rate (“CER”) basis, and that sales of its QuantiFERON product declined approximately 5% CER.
On this news, Qiagen’s stock price fell $4.07 per share, or 10.69%, to close at $34.02 per share on April 28, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. ("Qiagen" or the "Company") (NYSE: QGEN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Qiagen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On April 27, 2026, Qiagen announced preliminary results for the first quarter of 2026. Among other items, the Company disclosed that net sales declined approximately 1% on a constant exchange rate ("CER") basis, and that sales of its QuantiFERON product declined approximately 5% CER.
On this news, Qiagen's stock price fell $4.07 per share, or 10.69%, to close at $34.02 per share on April 28, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
